5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.18▲ | 2.17▲ | 2.17▲ | 2.06▲ | 2.16▲ |
MA10 | 2.18▲ | 2.16▲ | 2.11▲ | 2.09▲ | 2.65▼ |
MA20 | 2.17▲ | 2.11▲ | 2.07▲ | 2.12▲ | 3.01▼ |
MA50 | 2.16▲ | 2.06▲ | 2.07▲ | 2.76▼ | 3.26▼ |
MA100 | 2.10▲ | 2.08▲ | 2.08▲ | 2.99▼ | 2.93▼ |
MA200 | 2.06▲ | 2.08▲ | 2.20▼ | 3.33▼ | 2.56▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.006▲ | 0.019▲ | 0.042▲ | -0.140▼ |
RSI | 66.565▲ | 68.775▲ | 68.362▲ | 45.931▼ | 39.885▼ |
STOCH | 95.833▲ | 94.141▲ | 94.613▲ | 37.488 | 6.525▼ |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -22.973▲ | -89.286▼ |
CCI | 100.143▲ | 87.648 | 103.938▲ | 77.621 | -79.631 |
Wednesday, September 03, 2025 08:25 PM
(Reuters) -Exchange operator Nasdaq proposed on Wednesday stricter listing standards, including a higher minimum public float for certain new listings and a faster process to suspend and delist thinly ...
|
Thursday, August 28, 2025 09:05 AM
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
|
Wednesday, August 06, 2025 02:02 AM
4 analysts have shared their evaluations of Cardiff Oncology CRDF during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/09/25 | 2.07 | 2.19 | 2.05 | 2.185 | 704,628 |
17/09/25 | 2.01 | 2.095 | 2.00 | 2.01 | 500,298 |
16/09/25 | 2.02 | 2.06 | 1.98 | 2.00 | 732,753 |
15/09/25 | 2.08 | 2.08 | 1.97 | 2.04 | 846,452 |
12/09/25 | 2.09 | 2.10 | 2.04 | 2.05 | 606,287 |
11/09/25 | 2.04 | 2.11 | 2.04 | 2.08 | 588,772 |
10/09/25 | 2.13 | 2.14 | 2.03 | 2.04 | 707,400 |
09/09/25 | 2.20 | 2.2273 | 2.13 | 2.13 | 673,776 |
08/09/25 | 2.14 | 2.27 | 2.14 | 2.23 | 1,824,763 |
05/09/25 | 2.14 | 2.22 | 2.07 | 2.17 | 1,288,300 |
|
|
||||
|
|
||||
|
|